TNGX Stock Hits All-Time High – Wolfe Research Calls Tango Therapeutic’s Pancreatic Cancer Trial Data ‘Groundbreaking’
Tango Therapeutics’ experimental cancer drug Vopimetostat, in combination with Daraxonrasib, achieved a 92% objective response rate in patients with advanced pancreatic cancer. Wolfe raised the drug’s global peak sales estimate to about $2.6 billion from $1.9 billion. Mizuho analyst Joseph Catanzaro stated that the data ‘starts to tell a potentially very compelling signal of improved … Read more